About this trial

This is a prospective, double-blind, sham-controlled, multicenter, randomized clinical trial is to study the effects of remote ischemic preconditioning on contrast-associated acute kidney injury, functional capacity, and major adverse kidney events in in patients with congestive heart failure undergoing cardiac catheterization and/or percutaneous coronary intervention.

Eligibility criteria

Qualifiers

Age 18 years

Diagnosis of heart failure with reduced LVEF <50%

Pre-procedure intravenous normal saline fluid restriction status

Society for Cardiovascular Angiography and Interventions (SCAI) AKI risk score (>1%)

Disqualifiers

Inability to give informed consent

Unstable BP (SBP > 200 or <80 mmHg) at the time of enrolment

Upper limb peripheral arterial disease

Unavailability of at least one arm for RIPC/Sham-RIPC application

Trial design

Treatments tested in this trial

  • Remote ischemic preconditioning
  • Sham remote ischemic conditioning

Treatment groups

240 Participants
are divided into 2 treatment groups

Locations

3
VA Pittsburgh Healthcare System University Drive Division, Pittsburgh, PA15240, PittsburghPennsylvania, United States
VA North Texas Health Care System Dallas VA Medical Center, Dallas, TX75216-7167, DallasTexas, United States
Hunter Holmes McGuire VA Medical Center, Richmond, VA23249-0001, RichmondVirginia, United States

Sponsors and collaborators

VA Office of Research and Development

Lead sponsor